4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-013992
PRESIDENT AND CEO sold 5,000 shares at $16.49 ($82,453)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kintz Samuel PRESIDENT AND CEO | 2025-05-19 | Sale 10b5-1 | −5,000 | $16.49 | $82,453 | 972,892 | I: show line 1 in the form |
| Open-market sales · 5,000 sh · avg $16.49 · $82,453 | |||||||
Loading xslF345X05/form4-05212025_100549.xml…